180 related articles for article (PubMed ID: 36149214)
1. Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia.
Aigbe E; Irekpita E; Ogbetere FE; Alili UI
Niger J Clin Pract; 2022 Sep; 25(9):1523-1528. PubMed ID: 36149214
[TBL] [Abstract][Full Text] [Related]
2. Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer.
Avci S; Onen E; Caglayan V; Kilic M; Sambel M; Oner S
Arch Ital Urol Androl; 2020 Apr; 92(1):1-6. PubMed ID: 32255313
[TBL] [Abstract][Full Text] [Related]
3. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia.
Mao Q; Zheng X; Jia X; Wang Y; Qin J; Yang K; Bai Y; Xie L
Int Urol Nephrol; 2009 Dec; 41(4):761-6. PubMed ID: 19224388
[TBL] [Abstract][Full Text] [Related]
4. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
5. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
7. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
9. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
10. Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.
Zou BZ; Wen H; Luo HJ; Luo WC; Xie QT; Zhou MT
Ir J Med Sci; 2023 Dec; 192(6):2681-2687. PubMed ID: 37414978
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
[TBL] [Abstract][Full Text] [Related]
12. Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population.
Choi H; Park JY; Shim JS; Kim JH; Bae JH
Int Neurourol J; 2013 Jun; 17(2):73-7. PubMed ID: 23869271
[TBL] [Abstract][Full Text] [Related]
13. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
14. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
15. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia.
Coban S; Doluoglu OG; Keles I; Demirci H; Turkoglu AR; Guzelsoy M; Karalar M; Demirbas M
Aging Male; 2016 Jun; 19(2):124-7. PubMed ID: 26872869
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
17. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
18. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
[TBL] [Abstract][Full Text] [Related]
19. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
20. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer.
Xu D; Yu Y; Zhu Y; Huang T; Chen Y; Qi J
Pathol Oncol Res; 2014 Apr; 20(2):439-43. PubMed ID: 24178678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
